Lilly’s Prevail, Doudna’s Scribe Partner on Genetic Treatments for Neuro Diseases
BIOMARKER
1. Scribe Therapeutics and Eli Lilly subsidiary Prevail have entered into a strategic collaboration to develop CRISPR-based genetic medicines for neurological and neuromuscular indications.
2. Prevail will provide a $75 million upfront payment and equity investment in the collaboration.
3. Prevail has pledged over $1.5 billion in development and commercial milestones.
4. Scribe Therapeutics will receive additional research financing and tiered royalties on net future sales.
5. The collaboration will focus on developing in vivo treatments using Scribe's proprietary X-editing (XE) technologies.
6. XE technologies offer deliverability, specificity, and greater editing activity for therapeutic gene modification.
7. Scribe's CRISPR by Design platform is the foundation for the XE technologies, utilizing the bacterial immune system for genome editing.
8. The partnership will target neurological and neuromuscular indications, including Huntington's disease, spinal muscular atrophy, and Parkinson's disease.
9. Scribe is also working on genomic tools for sickle cell disease, glaucoma, Duchenne muscular dystrophy, and other indications.
10. Scribe Therapeutics, co-founded by Jennifer Doudna, has previously secured collaborations and investments with Biogen and Sanofi, and is recognized as a top life science startup.